180 Life Sciences’ (ATNF) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 180 Life Sciences (NASDAQ:ATNF) in a research note published on Saturday morning,Weiss Ratings reports.

180 Life Sciences Price Performance

ATNF stock opened at $1.11 on Friday. 180 Life Sciences has a 1-year low of $0.98 and a 1-year high of $17.75. The business’s 50 day simple moving average is $1.31 and its 200 day simple moving average is $2.00.

Hedge Funds Weigh In On 180 Life Sciences

A hedge fund recently bought a new stake in 180 Life Sciences stock. Rathbones Group PLC purchased a new stake in 180 Life Sciences Corp. (NASDAQ:ATNF) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned about 2.20% of 180 Life Sciences as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 4.07% of the company’s stock.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.